Catalent Acquires Nutraceutical for $1 Billion

Published on: 

Catalent’s acquisition of Bettera paves the way for growth in the softgel and oral dose formulation and manufacturing market for nutraceuticals.

Catalent has reached an agreement to acquire Bettera Holdings for $1 billion, according to a company press release from Aug. 30, 2021. Bettera Holdings is a manufacturer specializing in the production of gummy, soft chew, and lozenge nutritional supplements.

This acquisition will complement Catalent’s existing softgel and oral dose formulation and manufacturing services. It will expand Catalent’s current consumer health technology platform with a wider range of technologies and ready-to-market product libraries, as well as a variety of packaging options to meet customers’ branding needs.

The acquisition is expected to close in 2021. As part of the deal, Catalent will acquire approximately 500 employees from Bettera, as well as their production facilities in California, Indiana, New Jersey, and Virginia.


“This acquisition allows us to significantly accelerate the growth of our consumer health business and offer customers access to the substantial potential in gummies, soft chews, and lozenges, which are experiencing double-digit growth,” said Aris Gennadios, president of Softgel and Oral Technologies at Catalent, in the press release. “This acquisition is a key strategic move for Catalent’s Consumer Health business, where our leadership in manufacturing technologies and formulation can offer customers more product development opportunities, and add manufacturing capacity in this dynamic and fast-growing segment.”

Source: Catalent